<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Preclinical toxicological assessment of a novel monoclonal antibody targeting human platelet-derived growth factor CC (PDGF-CC) in PDGF-CC hum mice</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2018-07-18">July 18, 2018</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Manuel</forename><surname>Zeitelhofer</surname></persName>
							<email>manuel.zeitelhofer@ki.se</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Medical Biochemistry and Biophysics</orgName>
								<orgName type="institution">Karolinska Institutet</orgName>
								<address>
									<settlement>Stockholm</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Hong</forename><surname>Li</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Medical Biochemistry and Biophysics</orgName>
								<orgName type="institution">Karolinska Institutet</orgName>
								<address>
									<settlement>Stockholm</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Milena</forename><forename type="middle">Z</forename><surname>Adzemovic</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Medical Biochemistry and Biophysics</orgName>
								<orgName type="institution">Karolinska Institutet</orgName>
								<address>
									<settlement>Stockholm</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ingrid</forename><surname>Nilsson</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Medical Biochemistry and Biophysics</orgName>
								<orgName type="institution">Karolinska Institutet</orgName>
								<address>
									<settlement>Stockholm</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Lars</forename><surname>Muhl</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Medical Biochemistry and Biophysics</orgName>
								<orgName type="institution">Karolinska Institutet</orgName>
								<address>
									<settlement>Stockholm</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Andrew</forename><forename type="middle">M</forename><surname>Scott</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">School of Cancer Medicine</orgName>
								<orgName type="institution" key="instit1">Olivia Newton-John Cancer Research Institute</orgName>
								<orgName type="institution" key="instit2">La Trobe University</orgName>
								<address>
									<settlement>Melbourne</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ulf</forename><surname>Eriksson</surname></persName>
							<email>*ulf.pe.eriksson@ki.se</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Medical Biochemistry and Biophysics</orgName>
								<orgName type="institution">Karolinska Institutet</orgName>
								<address>
									<settlement>Stockholm</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff2">
								<orgName type="institution" key="instit1">Duke University School of Medicine</orgName>
								<orgName type="institution" key="instit2">UNITED STATES</orgName>
							</affiliation>
						</author>
						<title level="a" type="main">Preclinical toxicological assessment of a novel monoclonal antibody targeting human platelet-derived growth factor CC (PDGF-CC) in PDGF-CC hum mice</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2018-07-18">July 18, 2018</date>
						</imprint>
					</monogr>
					<idno type="MD5">143454B5DB5549659F88801955FB11A5</idno>
					<idno type="DOI">10.1371/journal.pone.0200649</idno>
					<note type="submission">Received: February 27, 2018 Accepted: June 30, 2018</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:44+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Platelet-derived growth factor CC (PDGF-CC) is important during foetal development but also in pathogenesis of neurologic diseases, cancer and fibrosis.</s><s>We have previously demonstrated that blocking the PDGF-CC/PDGF receptor alpha (PDGFRα) axis resulted in reduction of stroke volume and cerebrovascular permeability after experimentally induced stroke.</s><s>Recently, we could translate these findings into the clinic showing that imatinib, a small tyrosine kinase inhibitor targeting PDGF receptors, can significantly improve neurological outcome after ischemic stroke in human.</s><s>Herein we report preclinical toxicological analyses of our newly generated monoclonal anti-human PDGF-CC antibody 6B3 (mAb 6B3) in PDGF-CC humanized mice.</s><s>Beside histological organ assessment, we also analysed serum, urine, haematological parameters and the general health status of the treated mice.</s><s>We could not find any indications that mAb 6B3 is toxic or has other significant side effects neither in short, nor in long treatment regimens.</s><s>Our results indicate that mAb 6B3 can be further developed for clinical use.</s><s>This opens up the possibility to assess the therapeutic potential of blocking PDGF-CC in diverse pathological conditions such as neurologic diseases, cancer and fibrosis.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>Platelet-derived growth factor (PDGF)-CC is a member of the PDGF family and consists of a growth factor (GFD) and a N-terminal CUB (homology to complement components C1r/C1s, Uegf, BMP1) domain <ref type="bibr" target="#b0">[1]</ref>.</s><s>The CUB domain sterically blocks the receptor binding surface in the GFD and has to be proteolytically removed in order to release the GFD dimer and subsequently allow PDGF-CC to bind its receptor, PDGFRα <ref type="bibr" target="#b1">[2]</ref>.</s><s>Tissue type plasminogen activator (tPA) was identified as an enzyme that cleaves latent PDGF-CC <ref type="bibr" target="#b2">[3]</ref>.</s><s>We and others have previously shown that injection of tPA or active PDGF-CC into the cerebral spinal fluid (CSF) leads to increased permeability of the blood brain barrier (BBB) <ref type="bibr" target="#b3">[4]</ref>, <ref type="bibr" target="#b4">[5]</ref>, a hallmark of diverse pathological conditions of the central nervous system (CNS) <ref type="bibr" target="#b5">[6]</ref>.</s><s>Notably, the thrombolytic agent tPA is the only pharmaceutical treatment for ischemic stroke that is currently approved by the US Food and Drug Administration (FDA).</s><s>The treatment is, however, associated with neurotoxicity and an increased risk for haemorrhage, which affects 7% of stroke patients who received thrombolytic treatment and is associated with increased mortality <ref type="bibr" target="#b6">[7]</ref>.</s><s>The increased haemorrhage risk is possibly due to tPA mediated PDGF-CC activation which has been shown to increase BBB leakage <ref type="bibr" target="#b4">[5]</ref>.</s><s>Moreover, tPA can be administrated only within the first 4.5 hours after onset of the ischemic insult to achieve optimal therapeutic results <ref type="bibr" target="#b7">[8]</ref>.</s><s>Notably, up to 90% of all patients affected by stroke do not arrive in time to a hospital in order to receive tPA treatment <ref type="bibr" target="#b8">[9]</ref>.</s><s>Hence, blocking the side effects of tPA therapy would be of outmost importance to enable the treatment to a broader population of stroke patients by increasing the therapeutic window of tPA therapy.</s></p><p><s>We have shown that blocking PDGF receptor signalling with the small molecule tyrosine kinase inhibitor imatinib can reduce stroke volume in middle cerebral artery occlusion (MCAO), a mouse model of ischemic cerebrovascular insult <ref type="bibr" target="#b4">[5]</ref>.</s><s>Moreover, imatinib reduced BBB leakage and haemorrhagic complications when tPA was applied five hours after onset of MCAO <ref type="bibr" target="#b4">[5]</ref>.</s><s>In light of these experimental data, we recently performed a phase II randomized trial with imatinib in patients with acute ischemic stroke treated with intravenous thrombolysis <ref type="bibr" target="#b9">[10]</ref>.</s><s>This study showed that imatinib significantly ameliorates neurological symptoms with an improvement of 0.6 points per 100 mg imatinib on the National Institutes of Health Stroke Scale (NIHSS).</s><s>In the high dose group that received 800 mg imatinib, the mean adjusted NIHSS improvements were 5 points in comparison to the patients treated with tPA only.</s><s>In addition, inhibition of the PDGF-CC/PDGFRα axis has been shown to reduce BBB dysfunction, and has beneficial therapeutic effects in animal models of spinal cord injury (SCI) <ref type="bibr" target="#b10">[11]</ref>, multiple sclerosis (MS) <ref type="bibr" target="#b11">[12]</ref>, traumatic brain injury (TBI) <ref type="bibr" target="#b12">[13]</ref>, seizures <ref type="bibr" target="#b13">[14]</ref> and amyotrophic lateral sclerosis (ALS) <ref type="bibr" target="#b14">[15]</ref>.</s></p><p><s>Apart from neurological diseases involving BBB disruption, it has been shown that PDGF-CC can facilitate tumour growth by recruiting cancer-associated fibroblasts (CAFs) and by increasing tumour angiogenesis <ref type="bibr" target="#b15">[16]</ref>.</s><s>Interestingly, PDGF-CC mediated angiogenic and tumorigenic properties of fibroblasts were observed in tumours refractory to anti-VEGFA treatment <ref type="bibr" target="#b16">[17]</ref>.</s><s>Further, siRNA-mediated reduction of PDGF-CC expression reversed resistance to cisplatin and thus improved the outcome in models of squamous cell carcinoma <ref type="bibr" target="#b17">[18]</ref>.</s><s>It has also been reported that overexpression of PDGF-CC in vivo resulted in liver fibrosis, steatosis and hepatocellular carcinoma <ref type="bibr" target="#b18">[19]</ref> and that PDGF-CC mediates renal interstitial fibrosis <ref type="bibr" target="#b19">[20]</ref>.</s><s>Heart specific overexpression of PDGF-CC resulted in cardiac fibrosis, hypertrophy and dilated cardiomyopathy <ref type="bibr" target="#b20">[21]</ref>.</s><s>We have previously shown that Pdgfc deficiency in C57BL/6 mice is associated with various congenital defects <ref type="bibr" target="#b21">[22]</ref> which were also observed in tPA deficient mice <ref type="bibr" target="#b22">[23]</ref>.</s><s>In addition it has been demonstrated that Pdgfc deficient mice with 129/Sv background die in the perinatal period due to feeding and respiratory difficulties associated with a complete cleft of the secondary palate <ref type="bibr" target="#b23">[24]</ref>.</s><s>Thus, Pdgfc deficient mice are not suitable for analysing the potential therapeutic effect of PDGF-CC to treat numerous neurological disorders, cancer and fibrosis.</s></p><p><s>Thus, we aimed to generate a transgenic mouse expressing PDGF-CC with a humanized GFD (PDGF-CC hum ) that would allow us to neutralize PDGF-CC signalling in vivo using the anti-human PDGF-CC antibody 6B3 (mAb 6B3).</s><s>Here we report the generation and characterisation of PDGF-CC hum mice, and evaluated the toxological effects of neutralising PDGF-CC antibody 6B3 in these mice.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Material and methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Generation of PDGF-CC hum mice</head><p><s>The C57BL/6NTac-Pdgfc tm3633(K242T, K246R, R299S, K318R, N342S, A343T)Arte mice were generated by Taconic (Cologne, Germany) and are referred to as PDGF-CC hum throughout the publication.</s><s>The targeting strategy was based on NCBI transcript NM_019971_2.</s><s>Exon 1 contains the translation initiation codon.</s><s>To exchange the mouse with the human PDGFC six mutations were introduced into the mouse Pdgfc sequence.</s><s>K242T, K246R and R299S mutations have been introduced into exon 5.</s><s>The K318R, N342S and A343T mutations have been introduced into exon 6.</s><s>These mutations correspond to the human amino acid sequence.</s><s>Mouse genomic fragments (obtained from the C57BL/6J RPCIB-731 BAC library) and selected features (such as recombination sites and selection markers) were assembled into a targeting vector.</s><s>If necessary, additional fragments were amplified by qPCR and subcloned.</s><s>Positive selection markers have been flanked by FRT (Neomycin resistance-NeoR) and F3 (Puromycin resistance-PuroR) sites and have been inserted into intron 4 and intron 5, respectively.</s><s>The targeting vector has been generated using BAC clones from the C57BL/6J RPCIB-731 BAC library and was transfected into the TaconicArtemis C57BL/6N Tac embryonic stem cell (ES) line.</s><s>Homologous recombinant clones were isolated using double positive (NeoR and PuroR) and negative (Thymidine kinase-Tk) selections.</s><s>The constitutive humanized allele was obtained after in vitro Flp-mediated removal of the selection marker.</s><s>This allele expressed the mutated PDGF-CC K242T, K246R, R299S, K318R, N342S, A343T protein.</s><s>The remaining recombination sites were located in non-conserved regions of the genome.</s><s>PDGF-CC hum mice are available upon request.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Ethical statement</head><p><s>All experiments in this study were approved and performed in accordance with the guidelines from the Swedish National Board for Laboratory Animals and the European Community Council Directive (86/609/EEC) under the ethical permit N249/15, which was approved by the North Stockholm Animal Ethics Committee.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Animals and antibody treatment</head><p><s>PDGF-CC hum were originally obtained from Taconic (Germany).</s><s>The generation of Pdgfcdeficient mice has been described previously <ref type="bibr" target="#b23">[24]</ref>.</s><s>Animals were housed in the Scheele animal facility at the Karolinska Institute (Stockholm, Sweden) in a pathogen-free and climate-controlled environment in polystyrene cages containing aspen wood shavings with free access to standard rodent chow and water with regulated 12-hour light/dark cycles.</s></p><p><s>Four week old male or female PDGF-CC hum mice were injected intraperitoneally twice a week for either 10 days, 4 or 15 weeks with a weekly dose of 30 mg/kg (15 mg/kg per treatment) of either anti-PDGF-CC (6B3) or a control antibody (BM4).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cage side observations, weight measurements and urine analysis</head><p><s>Animals were monitored twice weekly according to the KI assessment checklist of health <ref type="bibr" target="#b24">[25]</ref>.</s><s>Thus the general health condition, porphyrin production, eyes, movements and posture, piloerection, respiration and skin were monitored.</s><s>Once per week the animals were weighed.</s><s>Two days before sacrificing urine samples were analysed using multistix (Siemens) or stored at -80 for further analysis.</s><s>The mouse organs (n = 5 per treatment) were weighed upon harvesting using an analytical scale (Sartorius).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Histopathological analyses and immunofluorescence (IF)</head><p><s>Animals were anesthetized using 4% isoflurane and perfused with HBSS followed by 4% paraformaldehyde (PFA).</s><s>After 4h long fixation in 4% PFA, the organs were cryo-protected in 20% sucrose, 4˚C over night (o/n) or paraffin embedded.</s><s>Twelve μm thick cryosections were used for IF as following: after air-drying for 30 minutes, 10 minutes long permeabilization step was performed in PBS/0,2% Triton-x100.</s><s>Blocking of unspecific binding was performed using PBS/10%FBS (blocking solution).</s><s>Subsequently, primary antibodies (humanized anti-human mAb 6B3 detecting human PDGF-CC and neuronal marker anti-NeuN (Merck, MAB377) were diluted in the blocking solution and applied o/n at 4˚C.</s><s>The signal was visualized using Alexa-Fluor conjugated secondary antibodies (Invitrogen).</s><s>DAPI was used for nucleus staining.</s><s>IF images were captured using a confocal microscope (Zeiss LSM700) and shown as 2D renderings of 10 μm-thick z-stacks.</s></p><p><s>Organ morphology was assessed on 4 μm-tick paraffin sections stained with Hematoxylin &amp; Eosin (H&amp;E) according to a standard protocol <ref type="bibr" target="#b11">[12]</ref>.</s><s>Representative images were captured using inverted microscope Axio Observer Z1 (Zeiss, Germany).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Clinical chemistry and hematology</head><p><s>Clinical chemistry and hematology analyses were performed by the University Animal Hospital, Swedish University of Agricultural Sciences, Uppsala, Sweden.</s><s>Mouse serum (n = 5 per sex and treatment group, respectively) was harvested after 15 weeks of antibody treatment.</s><s>ASAT, ALAT, albumin and calcium were analysed with spectrophotometry and the electrolytes (chloride, sodium and potassium) as well as conjugated bilirubin, total bilirubin, cholesterol, lipase, magnesium, triglycerides, amylase, iron, creatinine and creatine kinase were analysed with an ion specific electrode on an automated clinical chemistry analyser Architect c4000 (Abbott Laboratories, Abbott Park, IL, US) with commercial reagents from Abbott Laboratories.</s><s>All whole blood samples were analysed by an automated haematology analyzer as well as manually, using a microscope.</s><s>Leucocytes, neutrophils, eosinophils, basophiles, lymphocytes, monocytes, haemoglobin, erythrocytes, thrombocytes and reticulocytes were counted, mean cell haemoglobin concentration (MCHC) and mean cell volume (MCV) were calculated.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>mRNA generation and real time PCR analysis</head><p><s>mRNA was extracted from various organs using the RNeasy kit (Qiagen, Germany) and the QIAcube (Qiagen) including on column DNA-digestion for fully automated sample preparation.</s><s>RNA concentration and purity was determined through measurement of A260/A280 ratios with a NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies, Wilmington, USA).</s><s>Confirmation of RNA quality was assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).</s><s>mRNA was subsequently used for real time PCR analysis.</s><s>cDNA was prepared using the iScript kit (Biorrad, Hercules, USA).</s></p><p><s>Real-Time quantitative PCR was performed using KAPA SYBR FAST qPCR Kit (Kapa Biosystems, KM4101) in Rotor-Gene Q Real-Time PCR thermal cycler (Qiagen) according to the manufacturers' instructions.</s><s>Expression levels were normalized to the expression of L19 (GGTGACCTGGATGAGAAGGA and TTCAAGCTTGTGGATGTGCTC).</s><s>The following primers were used: Pdgfc hum : TCT CCT CAC CGA AGA GGT AAG GCT and GCT CTT CCC GTA TGG ACA CTG.</s><s>mouse Pdgfc: TCT CCT CAA GGA AGA GGT AAA ACT and GCT CTT CCC GTA TGG ACA CTG, Pdgfra: TGG CAT GAT GGT CGA TTC TA and CGC TGA GGT GGT AGA AGG AG.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p><s>GraphPad Prism software was used, and p values &lt; 0.05 were considered to indicate statistical significance.</s><s>Data are presented as mean ± SEM, and the number (n) of data points is from individual mice.</s><s>For analyses of mouse data ordinary one-way ANOVA with Tukey's test was used if more than two groups were compared, and Student's unpaired t test analysis was used for two-group comparisons.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Generation and characterization of the PDGF-CC hum mouse strain</head><p><s>We have generated and characterized a novel monoclonal antibody against human PDGF-CC called 6B3 <ref type="bibr" target="#b25">[26]</ref>.</s><s>mAb 6B3 was shown to block ligand induced phosphorylation of PDGFRα in vitro and blocks PDGF-CC mediated disruption of the blood retinal barrier (BRB) in vivo.</s><s>Since the antibody specifically recognizes human PDGF-CC, we generated a transgenic mouse containing Pdgfc with a partially humanized GFD.</s><s>Notably, mouse and human PDGF-CC GFD show high homology (Fig <ref type="figure" target="#fig_1">1A</ref>).</s><s>For humanization, 6 mutations were introduced into the GFD of the mouse Pdgfc genomic sequence.</s><s>K242T, K246R and R299S mutations were introduced into exon 5 and the K318R, N342S and A343T mutations were introduced into exon 6 (Fig <ref type="figure" target="#fig_1">1B</ref>).</s><s>The constitutive humanized allele was obtained after in vitro Flp-mediated removal of the selection marker.</s><s>This allele expressed the mutated PDGF-CC K242T, K246R, R299S, K318R, N342S, A343T protein (Fig <ref type="figure" target="#fig_1">1B</ref>).</s></p><p><s>To determine whether the humanization process was successful we analysed the health status of the PDGF-CC hum mice and the functionality of the partially humanized PDGF-CC protein.</s><s>Both male and female PDGF-CC hum mice had comparable body weight curve in comparison to their wild type (wt) littermates (Fig 1C <ref type="figure" target="#fig_1">and 1D</ref>).</s><s>In addition we analysed the gender ratio at weaning.</s><s>Heterozygous breeding demonstrated a normal Mendelian distribution of genotypes and genders (Fig <ref type="figure" target="#fig_1">1E</ref>).</s><s>As Pdgfc -/mice have reduced body weight <ref type="bibr" target="#b21">[22]</ref> we compared PDGF-CC hum , Pdgfc -/and wt littermates.</s><s>A representative image of the comparison of these 3 mouse strains showed that PGDF-CC hum and wt littermate controls are larger than Pdgfc -/mice (Fig <ref type="figure" target="#fig_1">1F</ref>).</s><s>In addition, we confirmed the expression of Pdgfc mRNA with the partially humanized GFD (Fig 2A <ref type="figure" target="#fig_2">and 2B</ref>).</s><s>Notably, mRNA levels of Pdgfc and Pdgfrα were similar in wt and PDGF-CC hum mice (Fig 2C <ref type="figure" target="#fig_2">and 2D</ref>).</s><s>Finally, we confirmed PDGF-CC protein expression in the PGDF-CC hum mouse brain, spleen and kidney (Fig 2E <ref type="figure" target="#fig_2">-2H</ref>).</s><s>PDGF-CC was expressed in cortical neurons <ref type="bibr">(Fig 2E)</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Assessment of systemic toxicity of the anti-PDGF-CC antibody 6B3</head><p><s>To assess potential target toxicity of mAb 6B3, we injected PDGF-CC hum mice intraperitoneally (i.p.) with a weekly dose of 30 mg/kg 6B3 or BM4, a control antibody.</s><s>The mice were treated twice a week (15mg/kg per treatment) starting from 4 weeks of age for either 10 days, 4 or 15 weeks.</s><s>Weight measurements were performed once a week until the end of the experiment.</s><s>In contrast to Pdgfc -/mice that suffer from weight loss due to underdevelopment <ref type="bibr" target="#b21">[22]</ref>, we could not observe any difference in weight between BM4-and 6B3-treated male (Fig 3A <ref type="figure">)</ref> and female (Fig 3B <ref type="figure">)</ref> PDGF-CC hum mice, respectively.</s><s>Moreover, we could not detect any difference in weight of various organs upon treatment with 6B3 and BM4, respectively (Fig <ref type="figure" target="#fig_3">3C</ref>).</s><s>The general health status of the mice was assessed twice a week (S1 and S2 Tables).</s><s>Both 6B3and BM4-treated PDGF-CC hum mice exhibited comparable activity, alertness and reaction to stimuli.</s><s>Their movement and posture were also normal.</s><s>The eyes were clear and showed no sign of infection/inflammation.</s><s>We further observed a normal respiration rate as well as a regular bowel and urinary function in both groups.</s><s>The urine analyses excluded abnormal levels of glucose or ketone bodies as well as the presence of leucocytes, nitrite and total protein (Fig <ref type="figure" target="#fig_3">3D</ref>).</s></p><p><s>To further assess potential systemic side effects of the 6B3 treatment, we analysed several haematological parameters in PDGF-CC hum mice after 10 days, and 15 weeks treatment with 6B3 and BM4, respectively.</s><s>The analyses included parameters reflecting liver function such as alanine and aspartate transaminases (ALAT and ASAT), muscle condition (creatine kinase), renal function (creatinine), lipid metabolism, electrolyte status, iron concentration, albumin, bilirubin etc. Notably, all these values were within the standard range in both groups, excluding potential functional organ/system impairment (Table <ref type="table" target="#tab_0">1</ref>).</s><s>We did not detect any difference in haemoglobin concentration, number of erythrocytes and various immune cells, between the groups after 10 days of treatment (S3 Table <ref type="table">)</ref>.</s><s>However, a 15 week-long treatment with mAb 6B3 showed a slight difference in hematocrit (p = 0.049) and the number of red blood cells (p = 0.029) between the control (BM4) and treatment (6B3) group, although all values were still within the normal range (Table <ref type="table" target="#tab_1">2</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Assessment of possible organ-specific toxicity of mAb 6B3</head><p><s>To further investigate potential side effects of a long-term treatment with mAb 6B3, we assessed various organs macroscopically and microscopically.</s><s>15 weeks after continuous treatment with 6B3 or BM4 antibodies, adrenal gland, brain, heart, kidney, liver, lung, pancreas, spleen, reproduction organs, skin, spinal cord, and thyroid gland in both groups did not exhibit signs of haemorrhage, edema, or any other macroscopic irregularity regarding organ morphology (Fig <ref type="figure" target="#fig_4">4</ref>).</s><s>In addition, we did not find any difference in weight of the brain, heart, kidney, liver, lung, and spleen between the treatment groups (Fig <ref type="figure" target="#fig_3">3C</ref>).</s><s>Histological analyses of the brain of 6B3 treated mice (Fig <ref type="figure" target="#fig_4">4</ref>) excluded asymmetry of the lateral ventricles, hypoplasia of the septum and a distorted ependymal lining of the lateral ventricles commonly found in Pdgfc -/mice <ref type="bibr" target="#b21">[22]</ref>.</s><s>Tissue sections of the kidney cortex and medulla did not show any signs of inflammation or fibrosis, and glomeruli and surrounding tubular structure appeared normal (Fig <ref type="figure" target="#fig_4">4</ref>).</s><s>In addition, creatinine serum levels, an indicator of kidney disease, did not differ between the treatment groups (Table <ref type="table" target="#tab_0">1</ref>).</s><s>The liver did not show any accumulation of lipids and the portal structure appeared normal with the portal vein in the center surrounded by the neat lining of sinusoids.</s><s>In addition, hepatocytes did not show any signs of hyperplasia <ref type="bibr">(Fig 4)</ref>.</s></p><p><s>Deletion of Pdgfc at developmental stage on 129/Sv genetic background resulted in perinatal lethality in mice due to enlarged lungs with thickened mesenchyme and poorly differentiated cells <ref type="bibr" target="#b23">[24]</ref>, <ref type="bibr" target="#b26">[27]</ref>.</s><s>Notably, lungs of the 6B3 treated mice were not enlarged or with distorted alveoli (Fig <ref type="figure" target="#fig_4">4</ref>).</s><s>Further, Pdgfc -/mice displayed mild dermal mesenchymal hypoplasia and skin blistering on a 129/Sv background <ref type="bibr" target="#b23">[24]</ref>.</s><s>We could not detect any blister formation, rash or other skin pathologies upon macroscopical examination of the mouse skin.</s><s>We therefore extended sites and have been inserted into intron 4 and intron 5, respectively.</s><s>The targeting vector was subsequently transfected into the TaconicArtemis C57BL/6N Tac embryonic stem cell (ES) line.</s><s>The constitutive humanized allele was obtained after in vitro Flp-mediated removal of the selection marker.</s><s>This allele expressed the mutated PDGF-CC K242T, K246R, R299S, K318R, N342S, A343T protein (B).</s><s>Weight curve between 8 and 16 weeks of age in male (C) and female (D) PDGF-CC hum .</s><s>Values in C-D represent mean +/-SEM (n = 10 for each genotype and gender) Distribution of genotypes and gender at weaning from heterozygous breedings (n = 57 litters).</s><s>PDGF-CC hum show Mendelian distribution of genotypes and even distribution of sexes (E).</s><s>Comparison of the body size between PDGFCC hum , PDGF-CC -/and wt littermate (F).</s></p><p><s>https://doi.org/10.1371/journal.pone.0200649.g001</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>We here present the phenotype of a novel PDGF-CC hum mouse, and the results of preclinical toxicological assessment of our recently generated mAb 6B3 targeting PDGF-CC.</s><s>The PDGF-CC hum mice were phenotypically normal and fertile, allowing in vivo assessment of effects of neutralization of PDGF-CC with mAb 6B3.</s><s>In addition to histological organ analyses, we analysed serum, urine, haematological parameters and the general health status of the treated mice.</s><s>There was a slight difference in RBC and hematocrit between 6B3 and BM4 treated mice, however the parameters were within the normal range in both treatment groups, and thus unlikely to be of clinical relevance.</s></p><p><s>We have previously described in detail the binding affinity and functional activity of 6B3 <ref type="bibr" target="#b25">[26]</ref> and shown that it blocks PDGF-CC induced phosphorylation of PDGFRα in vitro and thereby inhibits PDGFRα-mediated signalling.</s><s>Moreover, the antibody could block PDGF-CC induced opening of the BRB after intraocular injection of active PDGF-CC, indicating its potential to block PDGFRα signalling also in vivo <ref type="bibr" target="#b25">[26]</ref>.</s><s>The partially humanized PDGF-CC mouse strain used in this study is a suitable model for generating a reliable toxicological assessment of mAb 6B3 due to a similar PDGF-CC tissue expression in mice and human <ref type="bibr" target="#b25">[26]</ref>, <ref type="bibr" target="#b27">[28]</ref>.</s><s>Moreover, the antibody has a high affinity to human PDGF-CC, implying a possibility for use of 6B3 in human therapy.</s><s>Similar to our approach, Female or male PDGF-CC hum were i.p. injected with 6B3 (n = 5 for males and n = 4 for females unless stated otherwise) or BM4 (n = 5 for each gender unless stated otherwise) for 15 weeks and the serum parameters indicated in the table were analysed.</s><s>The indicated reference values are from biochemistry analysis of C57BL/6 mice from Charles River.</s><s>Reference values for conjugated bilirubin, lipase, magnesium amylase, iron, creatine kinase and hemolysis index were not available.</s><s>All serum parameters were analysed with Student's unpaired t test analysis was used and no significant difference was found for any parameter in males or females.</s><s>a: The serum of only 1 female mouse in the 6B3 group could be tested for Na and Cl; b: The serum of 3 female mice in the BM4 group could be tested for Na and Cl.</s></p><p><s>https://doi.org/10.1371/journal.pone.0200649.t001</s></p><p><s>humanized mice expressing human CD4 have been successfully used for toxicological assessment of a human anti-CD4 mAb keliximab, including pharmacokinetic/pharmacodynamic (PK/PD) profiling and single-and repeat-dose toxicity analyses <ref type="bibr" target="#b28">[29]</ref>, <ref type="bibr" target="#b29">[30]</ref>.</s></p><p><s>We have demonstrated that blocking PDGFRα signalling with the small molecule tyrosine kinase inhibitor imatinib decreased stroke volume and haemorrhagic transformation in MCAO <ref type="bibr" target="#b4">[5]</ref>.</s><s>Imatinib was also shown to improve neurological outcome in a phase II randomized trial in patients after acute ischemic stroke that were treated with intravenous thrombolysis <ref type="bibr" target="#b9">[10]</ref>.</s><s>In addition we demonstrated that PDGF-CC was upregulated in ALS and its animal model <ref type="bibr" target="#b14">[15]</ref>.</s><s>Hence, besides comparable expression pattern in mouse and human, similarities in the role of PDGF-CC in the human disease and the corresponding animal model additionally justify the use of the humanized mice for preclinical toxicological assessment instead of non-human primates.</s></p><p><s>Imatinib treatment was associated with cardiotoxicity in patients with chronic myeloid leukemia (CML), as well as with an abnormal bone and mineral metabolism <ref type="bibr" target="#b30">[31]</ref>.</s><s>In addition, imatinib is considered an unsuitable medication during pregnancy, based on preclinical data in mice <ref type="bibr" target="#b30">[31,</ref><ref type="bibr" target="#b31">32]</ref> and a retrospective study on pregnant women who received the treatment <ref type="bibr" target="#b32">[33]</ref>.</s><s>Furthermore, it has been observed that imatinib may alter liver parameters, and occasionally lead to liver failure <ref type="bibr" target="#b30">[31]</ref>.</s><s>Importantly, our results did not indicate any similar side effects upon treatment with mAb 6B3.</s></p><p><s>We have previously shown that Pdgfc deficiency in C57BL/6 mice is associated with various congenital defects such as abnormal vascular smooth muscle cell coverage, asymmetry of the lateral ventricles, hypoplasia of the septum and distorted ependymal lining of the lateral ventricles <ref type="bibr" target="#b21">[22]</ref>.</s><s>These defects were also observed in tPA deficient mice <ref type="bibr" target="#b22">[23]</ref>.</s><s>In addition, mice with Pdgfc deficiency and reduced Pdgfrα expression showed abnormal meningeal formation and neuronal over-migration in the cerebral cortex <ref type="bibr" target="#b26">[27]</ref>.</s><s>Notably, we could not find any of these defects in the 6B3-treated PDGF-CC hum mice.</s><s>Pdgfc -/mice also show decreased survival in the postnatal period (20%, instead of the 25% expected, survive when backcrossed onto a C57BL/6 background).</s><s>In addition, spontaneous death was found after the postnatal period in Pdgfc -/mice.</s><s>In contrast we could not observe any decrease in postnatal survival or spontaneous deaths after the postnatal period in PDGF-CC hum mice.</s><s>The oldest PDGF-CC hum mice so far are 22-23 months old.</s><s>They have been observed once a month since and we could not detect any alterations based on the clinical observations described in S1 and S2 Tables.</s><s>In addition we could not detect weight loss in PDGF-CC hum mice as seen in mice with Pdgfc ablation.</s><s>Thus PDGF-CC hum mice do not phenocopy Pdgfc -/mice and as a consequence the humanized PDGF-C in these mice is most probably cleaved and active.</s><s>In the present study, we managed to address essential requirements for generating a reliable preclinical toxicological assessment <ref type="bibr" target="#b33">[34]</ref> of mAb 6B3, which provided information about the status of organs/organ systems such as the liver, kidney, immune and hematopoietic system.</s><s>Analyses of the tissue morphology did not show any differences in the 6B3 compared to the control group.</s><s>The heart was excluded from histological analyses due to a very low expression level of PDGF-CC in this organ <ref type="bibr" target="#b20">[21]</ref>.</s><s>Nevertheless, we did not observe differences either in serum levels of creatine kinase or macroscopic changes in morphology and weight of the heart between the groups (Table <ref type="table" target="#tab_0">1</ref>, Fig <ref type="figure" target="#fig_3">3</ref>).</s><s>Thus, our clinical observations did not indicate any toxic effect in PDGF-CC hum mice upon treatment with mAb 6B3 (S1 and S2 Tables).</s><s>We could not detect any significant difference between the groups regarding amount of the immune cells.</s><s>These observations indicate that mAb 6B3 did not lead to any significant modulations of the immune system (Table <ref type="table" target="#tab_1">2 and S3 Table)</ref>.</s><s>Immune responses leading to the generation of anti-drug antibodies (ADA) can cause serious adverse events, but the most common problem is loss of efficacy, when ADAs bind the drug and neutralize its activity.</s><s>Thus if ADAs against mAb 6B3 would be developed we most probably would have detected side effects in the hematological or organ analysis.</s><s>In addition, we could not detect an increased number of serum lymphocytes of 6B3 compared to BM4 treated mice.</s><s>We analyzed Il2, important for clonal T cell proliferation, and Cd27 that plays a key role in regulating B-cell activation and immunoglobulin synthesis, in spleens after 3 months of 6B3 and BM4 injection and found similar levels than in non-injected controls (data not shown).</s><s>If ADAs against mAb 6B3 would be developed we would expect activation and clonal expansion of both CD4+ T cells and B cells which then would differentiate into antibody producing plasma cells.</s><s>Although being generally well tolerated, human recipients still may recognize parts of a therapeutic antibody as foreign, and thus activate immune and innate reactions <ref type="bibr" target="#b34">[35]</ref>.</s><s>Acute anaphylactic (IgE-mediated) or anaphylactoid reactions against a mAb in human cannot be ruled out entirely.</s><s>A clinical manifestation may range from local skin reaction at the injection site, an influenza-like syndrome to potentially fatal acute anaphylaxis and systemic inflammatory response syndrome <ref type="bibr" target="#b35">[36]</ref>.</s><s>Notably, we could not observe any of these reactions in our experimental animals.</s><s>Finally, it has been shown that mAbs may lead to tumour lysis syndrome (TlS) in patients <ref type="bibr" target="#b35">[36]</ref>.</s><s>To rule out this possible side effect, mAb 6B3 needs to be further tested in relevant mouse tumour model.</s><s>Though we have performed a careful preclinical toxicology analysis we plan to perform a dose escalation experiment before taking mAb 6B3 into the clinics.</s><s>In addition, we plan to perform toxicology and safety assessment together with PK/PD measurements in non-human primates.</s></p><p><s>Taken together, preclinical toxicological assessment of monoclonal anti-PDGF-CC mAb 6B3 did not indicate any significant systemic or organ alteration or side effects, upon both short-and long-term treatment with 6B3.</s><s>It is planned to take 6B3 into the clinic with the ultimate aim of treating different neuropathologies, cancer or fibrosis.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Supporting information</head><p><s>S1 Table <ref type="table">.</ref></s><s>Clinical observations (cage side) of PDGF-CC hum i.p. injected with 6B3 or BM4 twice weekly for either 10 days, 4 or 15 weeks.</s><s>Score 0.1 in the skin row indicates that the mice had small areas with fur loss.</s><s>A score system from 0 to 0.4 was used.</s><s>For explanation of the score system see S2 Table <ref type="table">.</ref></s><s>(DOCX) S2 Table <ref type="table">.</ref></s><s>Explanation of the score system for the clinical observations. 1</s><s>Porphyrin = redcoloured secretion from eyes (or nose). 2 Unsteady and has difficulty coordinating movements. 3</s><s>Hairs stand up and coat appears harsh.</s><s>Animal appears to be cold.</s></p><p><s>(DOCX) S3 Table.</s><s>Hematology analysis after 10 days injection of 6B3 or BM4.</s><s>Female PDGFCC hum were i.p. injected with 6B3 (n = 5 for each gender) or BM4 (n = 5 for each gender) two times within 10 days and hematology was analysed.</s><s>Statistics were calculated using Student's unpaired t test.</s><s>No significance was found for the analytes examined.</s><s>Mean reference value of C57BL/6 mouse hematology are from Jackson lab and Charles River, respectively.</s><s>Abbreviations: MCHC: mean cell hemoglobin concentration; MCV: mean cell volume.</s><s>(DOCX)</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><label></label><figDesc><div><p><s>and in blood vessels (Fig 2E and 2F) in the brain.</s><s>In the spleen PDGF-CC was expressed in T cell rich zones (Fig 2G) and in the kidney in tubular structures (Fig 2H).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig 1 .</head><label>1</label><figDesc><div><p><s>Fig 1. Construction and characterization of PDGF-CC hum mice.</s><s>The alignment of mouse and human PDGF-CC amino acid sequence is displayed.</s><s>Red arrows indicate those amino acids that were subjected to point mutations (A).</s><s>To exchange the mouse with the human PDGFC sequence 6 mutations were introduced into the mouse Pdgfc sequence.</s><s>K242T, K246R and R299S mutations have been introduced into exon 5.</s><s>The K318R, N342S and A343T mutations have been introduced into exon 6. Mouse genomic fragments and selected features (such as recombination sites and selection markers) were assembled into a targeting vector together with the 6 point mutations.</s><s>Positive selection markers have been flanked by FRT (Neomycin resistance-NeoR) and F3 (Puromycin resistance-PuroR)</s></p></div></figDesc><graphic coords="6,200.01,78.01,322.98,561.77" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Fig 2 .</head><label>2</label><figDesc><div><p><s>Fig 2. Humanized Pdgfc transcripts and PDGF-CC protein are expressed in PDGF-CC hum mice.</s><s>Primers specific for the mutated Pdgfc detect Pdgfc in PDGF-CC hum but not in wt mice (A).</s><s>Primers specific for mouse Pdgfc detect Pdgfc in wt but not in PDGF-CC hum mice (B).</s><s>Pdgfc (C) and Pdgfrα (D) transcript levels are similar in PDGF-CC hum and wt mice (n = 3 for PDGF-CC hum and wt mice, respectively).</s><s>Values in A-D represent mean +/-SEM.</s><s>Immunostaining with mAB 6B3 in the PDGF-CC hum mice (E-H).</s><s>shows PDGF-CC expression in neurons (E) and blood vessels (E and F) in the brain.</s><s>mAb 6B3 detects PDGF-CC in the spleen (G) and kidney (H).</s><s>scale bars: 30 u μm (E-G) and 10 μm (H).</s><s>https://doi.org/10.1371/journal.pone.0200649.g002</s></p></div></figDesc><graphic coords="8,200.01,78.01,335.91,558.37" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Fig 3 .</head><label>3</label><figDesc><div><p><s>Fig 3. Toxicology assessment of 6B3.</s><s>Female and male PDGFCC hum were intraperitoneally injected weekly with 30 mg/kg 6B3 (n = 5 for each gender) or BM4 (n = 5 for each gender) for 15 weeks.</s><s>Both male (A) and female (B) PDGF-CC hum mice treated with 6B3 did not show any weight alterations compared to BM4 treated mice.</s><s>Organs were harvested and the wet weight of the displayed organs did not differ between the 2 treatment groups (n = 5 for each treatment group) (C).</s><s>Urine was harvested after 15 weeks and the parameters indicated in the table analyzed (n = 5 for each treatment group) For the ph value SEM is indicated in brackets.</s><s>(D).</s><s>Values in A-C represent mean +/-SEM.</s><s>https://doi.org/10.1371/journal.pone.0200649.g003</s></p></div></figDesc><graphic coords="9,200.01,78.01,374.57,303.76" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Fig 4 .</head><label>4</label><figDesc><div><p><s>Fig 4. Long-term 6B3 treatment does not induce pathology of the major organs.</s><s>Female and male PDGFCC hum were intraperitoneally injected weekly with 30 mg/kg 6B3 (n = 5 for each gender) or BM4 (n = 5 for each gender) for 15 weeks.</s><s>Tissue sections of brain (A), kidney (B), liver (C), lung (D), pancreas (E), skin (F), spleen (G) and uterus (H) were stained with HE and their morphology and pathology evaluated.</s><s>Representative images of female mice are shown.</s><s>H: Hippocampus, E: Ependymal cells; G: Glomerulus; RC:; T: Trachea, AD: Alveolar duct, A: Aveoli; C: Centroacinar cells, E: Exocrine duct; F: B cell-rich follicle, T: T cell-rich zone.</s><s>https://doi.org/10.1371/journal.pone.0200649.g004</s></p></div></figDesc><graphic coords="12,95.92,78.01,480.02,373.78" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 . Serum parameters after 15 weeks of 6B3 or BM4 injection.</head><label>1</label><figDesc></figDesc><table><row><cell>Parameter</cell><cell>Unit</cell><cell>Male Range 6B3</cell><cell>Mean 6B3</cell><cell>SEM 6B3</cell><cell>Male Range BM4</cell><cell>Mean BM4</cell><cell>SEM BM4</cell><cell>Reference value males</cell></row><row><cell>ALAT</cell><cell>μkat/L</cell><cell>0.3-0.7</cell><cell>0.4</cell><cell>0.09</cell><cell>0.3-1.9</cell><cell>0.8</cell><cell>0.3</cell><cell>0.48-2.19</cell></row><row><cell>ASAT</cell><cell>μkat/L</cell><cell>1.3-3.7</cell><cell>2.3</cell><cell>0.5</cell><cell>2.3-9.0</cell><cell>5.5</cell><cell>1.2</cell><cell>0.76-6.51</cell></row><row><cell>Bilirubin. conjugated</cell><cell>μmol/L</cell><cell>1.8-2.0</cell><cell>1.8</cell><cell>0,0</cell><cell>1.8-1.8</cell><cell>1.8</cell><cell>0,0</cell><cell></cell></row><row><cell>S-bilirubin. total</cell><cell>μmol/L</cell><cell>1.8-3.9</cell><cell>2.6</cell><cell>0.3</cell><cell>1.8-2.6</cell><cell>2,0</cell><cell>0.2</cell><cell>3.4-10.2</cell></row><row><cell>Calcium</cell><cell cols="2">mmol/L 3.0-3.2</cell><cell>3.1</cell><cell>0,0</cell><cell>2.9-3.3</cell><cell>3.1</cell><cell>0.1</cell><cell>2.43-3.13</cell></row><row><cell>Cholesterol</cell><cell cols="2">mmol/L 1.7-3.9</cell><cell>3.2</cell><cell>0.4</cell><cell>2.5-3.4</cell><cell>2.8</cell><cell>0.1</cell><cell>1.74-4.39</cell></row><row><cell>Lipase</cell><cell>μkat/L</cell><cell>1.2-20.0</cell><cell>5.1</cell><cell>3.7</cell><cell>1.3-4.9</cell><cell>2.1</cell><cell>0.7</cell><cell></cell></row><row><cell>Magnesium</cell><cell cols="2">mmol/L 1.9-2.1</cell><cell>2,0</cell><cell>0,0</cell><cell>1.9-2.1</cell><cell>1.9</cell><cell>0.0</cell><cell></cell></row><row><cell>Triglycerides</cell><cell cols="2">mmol/L 1.1-2.1</cell><cell>1.5</cell><cell>0.2</cell><cell>1.1-2.2</cell><cell>1.6</cell><cell>0.2</cell><cell>0.77-3.20</cell></row><row><cell>Hemolysis index</cell><cell></cell><cell>0.6-1.2</cell><cell>0.8</cell><cell>0.1</cell><cell>0.7-2.2</cell><cell>1.2</cell><cell>0.2</cell><cell></cell></row><row><cell>Albumin</cell><cell>g/L</cell><cell>26.7-34.0</cell><cell>30.6</cell><cell>1.6</cell><cell>24.4-33.6</cell><cell>30.2</cell><cell>1.7</cell><cell>28-38</cell></row><row><cell>Amylas</cell><cell>μkat/L</cell><cell>17.0-93.0</cell><cell>36.3</cell><cell>14.3</cell><cell>22.4-49.2</cell><cell>28.4</cell><cell>5.2</cell><cell></cell></row><row><cell>Iron</cell><cell>μmol/L</cell><cell>33.2-41.4</cell><cell>36.8</cell><cell>1.6</cell><cell>20.0-36.2</cell><cell>30.1</cell><cell>2.7</cell><cell></cell></row><row><cell>kreatinin</cell><cell>μmol/L</cell><cell>15.1-18.0</cell><cell>16.6</cell><cell>0.5</cell><cell>11.6-16.0</cell><cell>14.8</cell><cell>0.8</cell><cell>17.39-43.48</cell></row><row><cell>Protein</cell><cell>g/L</cell><cell>53.1-65.3</cell><cell>60.2</cell><cell>2.4</cell><cell>53.2-64.6</cell><cell>59.6</cell><cell>1.9</cell><cell>48-70</cell></row><row><cell>CK</cell><cell>μkat/L</cell><cell>4.2-34.6</cell><cell>14.9</cell><cell>5.3</cell><cell>13.9-58.7</cell><cell>26.6</cell><cell>8.7</cell><cell></cell></row><row><cell>Na</cell><cell cols="2">mmol/L 147.0-150.6</cell><cell>149.4</cell><cell>0.8</cell><cell>147.0-150.2</cell><cell>148.8</cell><cell>0.5</cell><cell>145.2-176.2</cell></row><row><cell>Cl</cell><cell cols="2">mmol/L 109.8-111.6</cell><cell>110.7</cell><cell>0.3</cell><cell>106.5-114.8</cell><cell>112.1</cell><cell>1.5</cell><cell>110.7-129.8</cell></row><row><cell>Parameter</cell><cell>Unit</cell><cell>Female Range 6B3</cell><cell>Mean 6B3</cell><cell>SEM 6B3</cell><cell>Female Range BM4</cell><cell>Mean BM4</cell><cell>SEM BM4</cell><cell>Reference value females</cell></row><row><cell>ALAT</cell><cell>μkat/L</cell><cell>0.3-0.4</cell><cell>0.3</cell><cell>0,0</cell><cell>0.3-5.4</cell><cell>1.4</cell><cell>1.0</cell><cell>0.46-3.32</cell></row><row><cell>ASAT</cell><cell>μkat/L</cell><cell>2.1-4.3</cell><cell>3,0</cell><cell>0.5</cell><cell>1.6-6.2</cell><cell>3.6</cell><cell>0.8</cell><cell>0.71-6.59</cell></row><row><cell>Bilirubin. conjugated</cell><cell>μmol/L</cell><cell>1.8-1.8</cell><cell>1.8</cell><cell>0,0</cell><cell>1.8-2.5</cell><cell>1.9</cell><cell>0.1</cell><cell></cell></row><row><cell>S-bilirubin. total</cell><cell>μmol/L</cell><cell>2.3-3.1</cell><cell>2.6</cell><cell>0.2</cell><cell>1.8-4.7</cell><cell>2.9</cell><cell>0.5</cell><cell>3.4-10.2</cell></row><row><cell>Calcium</cell><cell cols="2">mmol/L 2.8-3.1</cell><cell>2.9</cell><cell>0.1</cell><cell>2.8-3.0</cell><cell>2.9</cell><cell>0.0</cell><cell>2.43-3.08</cell></row><row><cell>Cholesterol</cell><cell cols="2">mmol/L 2.2-2.3</cell><cell>2.3</cell><cell>0,0</cell><cell>1.8-2.1</cell><cell>2.0</cell><cell>0.0</cell><cell>1.43-4.26</cell></row><row><cell>Lipase</cell><cell>μkat/L</cell><cell>1.2-1.3</cell><cell>1.3</cell><cell>0,0</cell><cell>1.0-1.4</cell><cell>1.2</cell><cell>0.1</cell><cell></cell></row><row><cell>Magnesium</cell><cell cols="2">mmol/L 1.8-1.9</cell><cell>1.8</cell><cell>0,0</cell><cell>1.8-1.9</cell><cell>1.8</cell><cell>0.0</cell><cell></cell></row><row><cell>Triglycerides</cell><cell cols="2">mmol/L 1.0-1.4</cell><cell>1.2</cell><cell>0.1</cell><cell>0.8-1.4</cell><cell>1.1</cell><cell>0.1</cell><cell>0.86-3.32</cell></row><row><cell>Hemolysis index</cell><cell></cell><cell>0.8-1.0</cell><cell>0.9 a</cell><cell>0.1</cell><cell>n.d.</cell><cell>n.d.</cell><cell>n.d.</cell><cell></cell></row><row><cell>Albumin</cell><cell>g/L</cell><cell>33.3-34.9</cell><cell>34,0</cell><cell>0.3</cell><cell>31.6-34.4</cell><cell>32.9</cell><cell>0.5</cell><cell>24-43</cell></row><row><cell>Amylas</cell><cell>μkat/L</cell><cell>18.9-25.7</cell><cell>21.3</cell><cell>1.6</cell><cell>16.4-21.4</cell><cell>18.5</cell><cell>1.0</cell><cell></cell></row><row><cell>Iron</cell><cell>μmol/L</cell><cell>32.5-38.4</cell><cell>35.5 a</cell><cell>3,0</cell><cell>28.0-44.7</cell><cell>34.8</cell><cell>2.8</cell><cell></cell></row><row><cell>kreatinin</cell><cell>μmol/L</cell><cell>11.6-15.8</cell><cell>14.3</cell><cell>0.9</cell><cell>12.0-17.7</cell><cell>15.1</cell><cell>1.2</cell><cell>17.39-43.48</cell></row><row><cell>Protein</cell><cell>g/L</cell><cell>59.6-62.3</cell><cell>60.4</cell><cell>0.6</cell><cell>54.1-57.2</cell><cell>56.7</cell><cell>0.9</cell><cell>48-72</cell></row><row><cell>CK</cell><cell>μkat/L</cell><cell>7.6-16.6</cell><cell>11.6</cell><cell>2.3</cell><cell>5.2-16.2</cell><cell>11.0</cell><cell>1.9</cell><cell></cell></row><row><cell>Na</cell><cell>mmol/L</cell><cell></cell><cell>147.3 a</cell><cell></cell><cell>146.9-149.7</cell><cell>148.6 b</cell><cell>0.9</cell><cell>147.5-181.2</cell></row><row><cell>Cl</cell><cell>mmol/L</cell><cell></cell><cell>113.9 a</cell><cell></cell><cell>113.7-117.7</cell><cell>115.6 b</cell><cell>1.2</cell><cell>111.9-134.0</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2 . Hematology parameters after 15 weeks injections with 6B3 or BM4.</head><label>2</label><figDesc><div><p><s>Male PDGFCC hum were i.p. injected with 6B3 (n = 5) or BM4 (n = 5) for 15 weeks and hematologic parameters were analysed.</s><s>All hematology parameters were analysed using Student's unpaired t test and no significant difference was found for any parameter.</s><s>Ã Mean value of C57BL/6 mouse hematology from Jackson lab and Charles River, respectively.</s><s>Reticulocyte reference value only available from Jackson lab</s></p></div></figDesc><table><row><cell>Parameter</cell><cell>Unit</cell><cell>Male Range</cell><cell>Mean</cell><cell>SEM</cell><cell>Male Range</cell><cell>Mean</cell><cell>SEM</cell><cell>p value 6B3 vs</cell><cell>Reference</cell></row><row><cell></cell><cell></cell><cell>6B3</cell><cell>6B3</cell><cell>6B3</cell><cell>BM4</cell><cell>BM4</cell><cell>BM4</cell><cell>BM4</cell><cell>value Ã</cell></row><row><cell>Red blood cells (RBC)</cell><cell>10 6 /μL</cell><cell>9.0-9.4</cell><cell>9.24</cell><cell>0.07</cell><cell>8.3-9.2</cell><cell>8.8</cell><cell>0.15</cell><cell>0.029</cell><cell>9.48 or 10.62</cell></row><row><cell>Hemoglobin (HGB)</cell><cell>g/dL</cell><cell>13.0-13.2</cell><cell>13.1</cell><cell>0.05</cell><cell>12.3-13.3</cell><cell>12.8</cell><cell>0.20</cell><cell>0.163</cell><cell>14.2 or 16.0</cell></row><row><cell>Hematocrit (HCT)</cell><cell>% (of</cell><cell>45-47</cell><cell>46.4</cell><cell>0.40</cell><cell>42-47</cell><cell>44.2</cell><cell>0.86</cell><cell>0.049</cell><cell>46.6 or 51.8</cell></row><row><cell></cell><cell>blood)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Mean cell volume (MCV)</cell><cell>fL</cell><cell>50-51</cell><cell>50.4</cell><cell>0.25</cell><cell>49-51</cell><cell>50.2</cell><cell>0.37</cell><cell>0.666</cell><cell>49.2 or 48.8</cell></row><row><cell>Mean cell hemoglobin conc.</cell><cell>g/dL</cell><cell>27.5-29.1</cell><cell>28.3</cell><cell>0.28</cell><cell>28.3-29.8</cell><cell>29.0</cell><cell>0.28</cell><cell>0.098</cell><cell>30.2 or 31.1</cell></row><row><cell>(MCHC)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Reticulocytes</cell><cell>% (of</cell><cell>3.0-3.0</cell><cell>3.0</cell><cell>0</cell><cell>3.0-3.0</cell><cell>3.0</cell><cell>0</cell><cell></cell><cell>2.9</cell></row><row><cell></cell><cell>RBC)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>White blood cells (WBC)</cell><cell>10 3 /μL</cell><cell>2.2-7.6</cell><cell>4.38</cell><cell>0.15</cell><cell>1.0-4.2</cell><cell>2.34</cell><cell>0.53</cell><cell>0.145</cell><cell>8.9 or 3.1</cell></row><row><cell>Neutrophiles (NEUT)</cell><cell>10 3 /μL</cell><cell>0.3-5.1</cell><cell>2.02</cell><cell>1.05</cell><cell>0.1-0.3</cell><cell>0.18</cell><cell>0.04</cell><cell>0.117</cell><cell>1.44 or 1.17</cell></row><row><cell>Eosinophiles (EOS)</cell><cell>10 3 /μL</cell><cell>&lt;0.1-0.2</cell><cell></cell><cell></cell><cell>&lt;0.1-0.3</cell><cell></cell><cell></cell><cell></cell><cell>0.14 or 0.05</cell></row><row><cell>Basophils (BASO)</cell><cell>10 3 /μL</cell><cell>&lt;0.1-&lt;0.1</cell><cell></cell><cell></cell><cell>&lt;0.1-&lt;0.1</cell><cell></cell><cell></cell><cell></cell><cell>0.03 or 0.01</cell></row><row><cell>Lymphocytes (LYMPH)</cell><cell>10 3 /μL</cell><cell>1.7-2.5</cell><cell>2.06</cell><cell>0.15</cell><cell>0.9-3.6</cell><cell>1.96</cell><cell>0.46</cell><cell>0.842</cell><cell>6.87 or 1.8</cell></row><row><cell>Monocytes (MONO)</cell><cell>10 3 /μL</cell><cell>0.1-0.5</cell><cell>0.22</cell><cell>0.08</cell><cell>0.0-0.1</cell><cell>0.08</cell><cell>0.02</cell><cell>0.128</cell><cell>0.41 or 0.06</cell></row></table><note><p><s>https://doi.org/10.1371/journal.pone.0200649.t002</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">PLOS ONE | https://doi.org/10.1371/journal.pone.0200649July 18, 2018  </note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgments</head><p><s>We would like to thank Linda Fredriksson, PhD for providing the Pdgfc -/mice.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Author Contributions</head><p><s>Conceptualization: Ulf Eriksson.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor</title>
		<author>
			<persName><forename type="first">X</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ponten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Aase</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Karlsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Abramsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Uutela</surname></persName>
		</author>
		<idno type="DOI">10.1038/35010579</idno>
		<idno type="PMID">10806482</idno>
		<ptr target="https://doi.org/10.1038/35010579" />
	</analytic>
	<monogr>
		<title level="j">Nat Cell Biol</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="302" to="309" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<monogr>
		<title level="m" type="main">The PDGF family: four gene products form five dimeric isoforms. Cytokine Growth Factor Rev</title>
		<author>
			<persName><forename type="first">L</forename><surname>Fredriksson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Eriksson</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.cytogfr.2004.03.007</idno>
		<idno type="PMID">15207811</idno>
		<ptr target="https://doi.org/10.1016/j.cytogfr.2004.03.007" />
		<imprint>
			<date type="published" when="2004-06-23">2004. 2004/06/23</date>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="197" to="204" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Tissue plasminogen activator is a potent activator of PDGF-CC</title>
		<author>
			<persName><forename type="first">L</forename><surname>Fredriksson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Fieber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Eriksson</surname></persName>
		</author>
		<idno type="DOI">10.1038/sj.emboj.7600397</idno>
		<idno type="PMID">15372073</idno>
		<ptr target="https://doi.org/10.1038/sj.emboj.7600397" />
	</analytic>
	<monogr>
		<title level="j">The EMBO journal</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">19</biblScope>
			<biblScope unit="page" from="3793" to="3802" />
			<date type="published" when="2004-09-17">2004. 2004/09/17</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein</title>
		<author>
			<persName><forename type="first">M</forename><surname>Yepes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sandkvist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">G</forename><surname>Moore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">H</forename><surname>Bugge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">K</forename><surname>Strickland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Lawrence</surname></persName>
		</author>
		<idno type="DOI">10.1172/JCI19212</idno>
		<idno type="PMID">14617754</idno>
		<ptr target="https://doi.org/10.1172/JCI19212" />
	</analytic>
	<monogr>
		<title level="j">The Journal of clinical investigation</title>
		<imprint>
			<biblScope unit="volume">112</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1533" to="1540" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Su</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Fredriksson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Geyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Folestad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Cale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Andrae</surname></persName>
		</author>
		<idno type="DOI">10.1038/nm1787</idno>
		<idno type="PMID">18568034</idno>
		<ptr target="https://doi.org/10.1038/nm1787" />
	</analytic>
	<monogr>
		<title level="j">Nat Med</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="731" to="737" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">The blood-brain barrier in health and disease</title>
		<author>
			<persName><forename type="first">R</forename><surname>Daneman</surname></persName>
		</author>
		<idno type="DOI">10.1002/ana.23648</idno>
		<idno type="PMID">23280789</idno>
		<ptr target="https://doi.org/10.1002/ana.23648" />
	</analytic>
	<monogr>
		<title level="j">Annals of neurology</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="648" to="672" />
			<date type="published" when="2012">2012. 2013/01/03</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Thrombolysis with alteplase for acute ischemic stroke: review of SITS-MOST and other Phase IV studies</title>
		<author>
			<persName><forename type="first">S</forename><surname>Kulkens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Hacke</surname></persName>
		</author>
		<idno type="DOI">10.1586/14737175.7.7.783</idno>
		<idno type="PMID">17610385</idno>
		<ptr target="https://doi.org/10.1586/14737175.7.7.783" />
	</analytic>
	<monogr>
		<title level="j">Expert Rev Neurother</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="783" to="788" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">N</forename><surname>Whiteley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Emberson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">R</forename><surname>Lees</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Blackwell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Albers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Bluhmki</surname></persName>
		</author>
		<idno type="DOI">10.1016/S1474-4422(16)30076-X</idno>
		<idno type="PMID">27289487</idno>
		<ptr target="https://doi.org/10.1016/S1474-4422(16)30076-X" />
	</analytic>
	<monogr>
		<title level="j">Lancet Neurol</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="925" to="933" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Influence of the stroke code activation source on the outcome of acute ischemic stroke patients</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">P</forename><surname>De La Ossa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Sanchez-Ojanguren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Palomeras</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Millan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Arenillas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Dorado</surname></persName>
		</author>
		<idno type="DOI">10.1212/01.wnl.0000291008.63002.a5</idno>
		<idno type="PMID">18322264</idno>
		<ptr target="https://doi.org/10.1212/01.wnl.0000291008.63002.a5" />
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="issue">15</biblScope>
			<biblScope unit="page" from="1238" to="1243" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Randomized assessment of imatinib in patients with acute ischaemic stroke treated with intravenous thrombolysis</title>
		<author>
			<persName><forename type="first">N</forename><surname>Wahlgren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Thoren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Hojeberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">B</forename><surname>Kall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Laska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Sjostrand</surname></persName>
		</author>
		<idno type="DOI">10.1111/joim.12576</idno>
		<idno type="PMID">27862464</idno>
		<ptr target="https://doi.org/10.1111/joim.12576" />
	</analytic>
	<monogr>
		<title level="j">J Intern Med</title>
		<imprint>
			<biblScope unit="volume">281</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="273" to="283" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Imatinib enhances functional outcome after spinal cord injury</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Abrams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Nilsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Lewandowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kjell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Codeluppi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Olson</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0038760</idno>
		<idno type="PMID">22723886</idno>
		<ptr target="https://doi.org/10.1371/journal.pone.0038760" />
	</analytic>
	<monogr>
		<title level="j">PloS one</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">6</biblScope>
			<date type="published" when="2012-06-23">2012. 2012/06/23</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Imatinib ameliorates neuroinflammation in a rat model of multiple sclerosis by enhancing blood-brain barrier integrity and by modulating the peripheral immune response</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">V</forename><surname>Adzemovic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zeitelhofer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Eriksson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Olsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Nilsson</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0056586</idno>
		<idno type="PMID">23437178</idno>
		<ptr target="https://doi.org/10.1371/journal.pone.0056586" />
	</analytic>
	<monogr>
		<title level="j">PloS one</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">2</biblScope>
			<date type="published" when="2013-02-26">2013. 2013/02/26</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Imatinib treatment reduces brain injury in a murine model of traumatic brain injury</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Su</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Fredriksson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kanzawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Moore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Folestad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">K</forename><surname>Stevenson</surname></persName>
		</author>
		<idno type="DOI">10.3389/fncel.2015.00385</idno>
		<idno type="PMID">26500491</idno>
		<ptr target="https://doi.org/10.3389/fncel.2015.00385" />
	</analytic>
	<monogr>
		<title level="j">Front Cell Neurosci</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">385</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Identification of a neurovascular signaling pathway regulating seizures in mice</title>
		<author>
			<persName><forename type="first">L</forename><surname>Fredriksson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">K</forename><surname>Stevenson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Su</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ragsdale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Moore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Craciun</surname></persName>
		</author>
		<idno type="DOI">10.1002/acn3.209</idno>
		<idno type="PMID">26273685</idno>
		<ptr target="https://doi.org/10.1002/acn3.209" />
	</analytic>
	<monogr>
		<title level="j">Ann Clin Transl Neurol</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="722" to="738" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<monogr>
		<title level="m" type="main">Presymptomatic activation of the PDGF-CC pathway accelerates onset of ALS neurodegeneration. Acta neuropathologica</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Lewandowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Nilsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Fredriksson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lonnerberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Muhl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zeitelhofer</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00401-015-1520-2</idno>
		<idno type="PMID">26687981</idno>
		<ptr target="https://doi.org/10.1007/s00401-015-1520-2" />
		<imprint>
			<date type="published" when="2016">2016</date>
			<biblScope unit="volume">131</biblScope>
			<biblScope unit="page" from="453" to="464" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<monogr>
		<title level="m" type="main">Paracrine signaling by plateletderived growth factor-CC promotes tumor growth by recruitment of cancer-associated fibroblasts. Cancer Res</title>
		<author>
			<persName><forename type="first">C</forename><surname>Anderberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Fredriksson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Andrae</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Betsholtz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Li</surname></persName>
		</author>
		<idno type="DOI">10.1158/0008-5472.CAN-08-2724</idno>
		<idno type="PMID">19118022</idno>
		<ptr target="https://doi.org/10.1158/0008-5472.CAN-08-2724" />
		<imprint>
			<date type="published" when="2009-01-02">2009. 2009/01/02</date>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="369" to="378" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Crawford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Kasman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Zhong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Modrusan</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ccr.2008.12.004</idno>
		<idno type="PMID">19111878</idno>
		<ptr target="https://doi.org/10.1016/j.ccr.2008.12.004" />
	</analytic>
	<monogr>
		<title level="j">Cancer Cell</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="21" to="34" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Identification of cisplatinresistance related genes in head and neck squamous cell carcinoma</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Yamano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Uzawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Saito</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Nakashima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kasamatsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Koike</surname></persName>
		</author>
		<idno type="DOI">10.1002/ijc.24704</idno>
		<idno type="PMID">19569180</idno>
		<ptr target="https://doi.org/10.1002/ijc.24704" />
	</analytic>
	<monogr>
		<title level="j">Int J Cancer</title>
		<imprint>
			<biblScope unit="volume">126</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="437" to="449" />
			<date type="published" when="2009-07-02">2010. 2009/07/02</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Campbell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Hughes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Gilbertson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">E</forename><surname>Palmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Holdren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Haran</surname></persName>
		</author>
		<idno type="DOI">10.1073/pnas.0409722102</idno>
		<idno type="PMID">15728360</idno>
		<ptr target="https://doi.org/10.1073/pnas.0409722102" />
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci U S A</title>
		<imprint>
			<biblScope unit="volume">102</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="3389" to="3394" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">PDGF-C is a proinflammatory cytokine that mediates renal interstitial fibrosis</title>
		<author>
			<persName><forename type="first">F</forename><surname>Eitner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Bucher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Van Roeyen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Kunter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Seikrit</surname></persName>
		</author>
		<idno type="DOI">10.1681/ASN.2007030290</idno>
		<idno type="PMID">18184860</idno>
		<ptr target="https://doi.org/10.1681/ASN.2007030290" />
	</analytic>
	<monogr>
		<title level="j">J Am Soc Nephrol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="281" to="289" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Transgenic overexpression of plateletderived growth factor-C in the mouse heart induces cardiac fibrosis, hypertrophy, and dilated cardiomyopathy</title>
		<author>
			<persName><forename type="first">A</forename><surname>Ponten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Thoren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Aase</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Sjoblom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ostman</surname></persName>
		</author>
		<idno type="DOI">10.1016/S0002-9440(10)63694-2</idno>
		<idno type="PMID">12875986</idno>
		<ptr target="https://doi.org/10.1016/" />
	</analytic>
	<monogr>
		<title level="j">Am J Pathol</title>
		<imprint>
			<biblScope unit="volume">163</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="673" to="682" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Platelet-derived growth factor C deficiency in C57BL/6 mice leads to abnormal cerebral vascularization, loss of neuroependymal integrity, and ventricular abnormalities</title>
		<author>
			<persName><forename type="first">L</forename><surname>Fredriksson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Nilsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Su</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Andrae</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Ding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Betsholtz</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ajpath.2011.12.006</idno>
		<idno type="PMID">22230248</idno>
		<ptr target="https://doi.org/10.1016/j.ajpath.2011.12.006" />
	</analytic>
	<monogr>
		<title level="j">Am J Pathol</title>
		<imprint>
			<biblScope unit="volume">180</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="1136" to="1144" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">tPA Deficiency in Mice Leads to Rearrangement in the Cerebrovascular Tree and Cerebroventricular Malformations</title>
		<author>
			<persName><forename type="first">C</forename><surname>Stefanitsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Lawrence</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Olverling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Nilsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Fredriksson</surname></persName>
		</author>
		<idno type="DOI">10.3389/fncel.2015.00456</idno>
		<idno type="PMID">26648843</idno>
		<ptr target="https://doi.org/10.3389/fncel.2015.00456" />
	</analytic>
	<monogr>
		<title level="j">Front Cell Neurosci</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">456</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">A specific requirement for PDGF-C in palate formation and PDGFR-alpha signaling</title>
		<author>
			<persName><forename type="first">H</forename><surname>Ding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Bostrom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Wong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Tsoi</surname></persName>
		</author>
		<idno type="DOI">10.1038/ng1415</idno>
		<idno type="PMID">15361870</idno>
		<ptr target="https://doi.org/10.1038/ng1415" />
	</analytic>
	<monogr>
		<title level="j">Nature genetics</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1111" to="1116" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Assessment of health status of small rodents and rabbits when illness is suspected</title>
		<idno>2015-11-20</idno>
		<ptr target="https://internwebbenkise/en/node/11930" />
	</analytic>
	<monogr>
		<title level="j">Karolinska Institutet</title>
		<imprint>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Development of monoclonal anti-PDGF-CC antibodies as tools for investigating tissue expression in humans and for blocking PDGFRα signalling in vivo</title>
		<author>
			<persName><forename type="first">H</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zeitelhofer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Nilsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Scott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Scott</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Plos One</title>
		<imprint>
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note>accepted for publoication</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">A role for PDGF-C/PDGFRalpha signaling in the formation of the meningeal basement membranes surrounding the cerebral cortex</title>
		<author>
			<persName><forename type="first">J</forename><surname>Andrae</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Gouveia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gallini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Fredriksson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Nilsson</surname></persName>
		</author>
		<idno type="DOI">10.1242/bio.017368</idno>
		<idno type="PMID">26988758</idno>
		<ptr target="https://doi.org/10.1242/bio.017368" />
	</analytic>
	<monogr>
		<title level="j">Biol Open</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="461" to="474" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Expression analysis of PDGF-C in adult and developing mouse tissues</title>
		<author>
			<persName><forename type="first">K</forename><surname>Aase</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Abramsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Karlsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Betsholtz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Eriksson</surname></persName>
		</author>
		<idno type="PMID">11744381</idno>
	</analytic>
	<monogr>
		<title level="j">Mech Dev</title>
		<imprint>
			<biblScope unit="volume">110</biblScope>
			<biblScope unit="issue">1-2</biblScope>
			<biblScope unit="page" from="187" to="191" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Comparative pharmacodynamics of keliximab and clenoliximab in transgenic mice bearing human CD4</title>
		<author>
			<persName><forename type="first">A</forename><surname>Sharma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">B</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Tobia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Kwok</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Tucci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">R</forename><surname>Gore</surname></persName>
		</author>
		<idno type="PMID">10734150</idno>
	</analytic>
	<monogr>
		<title level="j">J Pharmacol Exp Ther</title>
		<imprint>
			<biblScope unit="volume">293</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="33" to="41" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Inhibition of contact sensitivity in human CD4 + transgenic mice by human CD4-specific monoclonal antibodies: CD4+ T-cell depletion is not required</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>Podolin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">F</forename><surname>Webb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Reddy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Truneh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Griswold</surname></persName>
		</author>
		<idno type="DOI">10.1046/j.1365-2567.2000.00946.x</idno>
		<idno type="PMID">10692049</idno>
		<ptr target="https://doi.org/10.1046/j.1365-2567.2000.00946.x" />
	</analytic>
	<monogr>
		<title level="j">Immunology</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="287" to="295" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">I</forename><surname>Mughal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Schrieber</surname></persName>
		</author>
		<idno type="DOI">10.2147/BTT.S5775</idno>
		<idno type="PMID">21209726</idno>
		<ptr target="https://doi.org/10.2147/BTT.S5775" />
	</analytic>
	<monogr>
		<title level="j">Biologics</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="315" to="323" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Mice homozygous for the ablm1 mutation show poor viability and depletion of selected B and T cell populations</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>Schwartzberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Stall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Hardin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Bowdish</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Humaran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Boast</surname></persName>
		</author>
		<idno type="PMID">2065353</idno>
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="1165" to="1175" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">The effects of imatinib on pregnancy outcome</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Pye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Cortes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ault</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hatfield</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kantarjian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Pilot</surname></persName>
		</author>
		<idno type="DOI">10.1182/blood-2007-10-114900</idno>
		<idno type="PMID">18322153</idno>
		<ptr target="https://doi.org/10.1182/blood-2007-10-114900" />
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">111</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="5505" to="5508" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Practical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodies</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Lynch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">W</forename><surname>Hart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">S</forename><surname>Grewal</surname></persName>
		</author>
		<idno type="PMID">20046568</idno>
	</analytic>
	<monogr>
		<title level="j">MAbs</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="2" to="11" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Engineering of therapeutic antibodies to minimize immunogenicity and optimize function</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">G</forename><surname>Presta</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.addr.2006.01.026</idno>
		<idno type="PMID">16904789</idno>
		<ptr target="https://doi.org/10.1016/j.addr.2006.01.026" />
	</analytic>
	<monogr>
		<title level="j">Adv Drug Deliv Rev</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="issue">5-6</biblScope>
			<biblScope unit="page" from="640" to="656" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">The safety and side effects of monoclonal antibodies</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">T</forename><surname>Hansel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kropshofer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Singer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Mitchell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>George</surname></persName>
		</author>
		<idno type="DOI">10.1038/nrd3003</idno>
		<idno type="PMID">20305665</idno>
		<ptr target="https://doi.org/10.1038/nrd3003" />
	</analytic>
	<monogr>
		<title level="j">Nat Rev Drug Discov</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="325" to="338" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
